Numbers

The Numbers

Centene trades at the lowest price-to-sales ratio in its 20-year history (0.11x vs a 20y median of 0.74x) on a $194.8B revenue base that is still growing 19% per year. The market is paying as if FY2025's $6.7B goodwill write-down and 360 bps blow-out in medical loss ratio are permanent, even though management is guiding to greater than $3.00 of adjusted EPS for 2026 and operating cash flow rebounded to $5.1B in 2025. The single number that re-rates this stock is the Health Benefits Ratio: 91.9% in 2025 versus an 87–88% historical band — every 100 bps of mean reversion is roughly $1.7B of pre-tax earnings.

1. Quality scorecard — is this business durable?

There is no escaping that 2025 was the worst year on record for Centene. But the right test of durability is across cycles, not at the bottom of one. Five reads on quality from the 20 years of statements:

The quality story is split. Cash generation, leverage, and operating-margin stability are durable through cycles — Centene survived the 2017 ACA wobble, the 2020 COVID surge, and the 2022 trend mini-cycle without the balance sheet ever flashing red. What is not durable is the ROE: returns on equity have averaged below 10% even in good years, because every dollar of premium revenue requires capital reserves and the WellCare-era goodwill ($17.6B of carrying value pre-impairment) was never going to compound at insurance-company returns. The FY2025 impairment was a quiet acknowledgement that the M&A roll-up was overpaid.

2. Revenue and earnings power — 20 years

Revenue compounded at 26% annually for 20 years — almost all of it through state Medicaid contract wins and three large acquisitions (HealthNet 2016, Fidelis 2018, WellCare 2020). The margin chart is the more honest picture: this has never been a high-margin business. Operating margin has lived in a 1–3% corridor for the entire post-IPO history, and even peak years like FY2020 (a COVID utilization gift) only hit 2.8%. The FY2025 -3.9% operating margin is not a margin re-base — it is the $6.7B goodwill write-down sitting inside operating expenses.

The split is exact: revenue accelerated through 2024–2025 (Medicaid acuity drove PMPM higher, IRA Part D inflated PDP premiums, Marketplace grew before the EAPTC sunset), but operating income collapsed in Q3 2025 when the goodwill write-down was taken. Strip the impairment and Q2/Q3/Q4 2025 still show the underwriting wound — Q4 2025 Medicaid HBR of 93.0% is 360 bps above the 2024 baseline.

3. Cash conversion — earnings vs cash

This is the section that separates Centene from the GAAP narrative. In an insurance business, premium dollars come in fast and claims pay out slow — so operating cash flow regularly exceeds reported net income, and reading only the income statement misses the actual economic engine.

Over the last decade, Centene generated $28.2B of cumulative free cash flow on $7.3B of cumulative net income — a 3.9x ratio. That gap is float: Medicaid and Marketplace plans collect premiums monthly and pay claims with a 30–60 day lag, so growing membership generates working-capital cash before it shows up as profit. The flip side appeared in FY2024: rising Marketplace risk-adjustment receivables and CMS Medicare pass-throughs swelled by billions, dropping FCF to negative $490M even though net income hit a record $3.3B. FY2025 reversed exactly that working-capital build, which is why a $6.7B GAAP loss still produced $4.3B of free cash. Read the cash flow statement first; the income statement is the noisier signal in this business.

4. Capital allocation — where the cash went

Three eras of capital allocation. Through 2019, every dollar went into M&A — HealthNet ($6.3B, 2016), Fidelis ($3.7B, 2018), and WellCare ($17.4B, 2020). From 2021 onwards, M&A stopped and buybacks turned on hard: $14.5B of share repurchases in five years, retiring 17% of the share count from a peak of 591M in 2021 to 491M today. Dividends have never been a feature of this story (one one-time $6.1B special return-of-capital in 2018, otherwise zero). The 2025 buyback pace slowed to $1.5B as management defended the balance sheet through the impairment cycle — a rational call but a signal that capital deployment will be subdued through 2026.

5. Balance sheet — flexibility, not stress

The leverage chart is the rebuttal to the "Centene is in trouble" narrative. Total debt has been flat to declining since the 2021 WellCare-financing peak of $22.7B; cash on the balance sheet has actually grown to $17.9B at year-end 2025, so net debt is essentially nil. The FY2025 D/E spike to 0.94x is mechanical — the goodwill write-down shrank equity from $26.4B to $20.0B, but the debt did not move. Centene retained its investment-grade ratings through the impairment, and the credit facility was renegotiated in 2025 at favorable rates.

6. Valuation — where the multiple stands today

This is the chart that decides the thesis. Because FY2025 booked a GAAP loss, P/E is mechanically meaningless; the cleaner historical anchor for a regulated insurer is price-to-sales, which is invariant to one-time write-downs.

Centene has never traded this cheap on revenue. Current P/S of 0.11x is 86% below the 20-year median (0.74x) and 58% below the 5-year mean (0.26x). The caveat is that revenue growth has come increasingly from low-margin pass-throughs (PDP, risk-adjustment), so the right comparison is probably the 5-year average. Even on that basis, the stock is roughly 2 standard deviations cheap and pricing in close to zero earnings recovery for the next 24 months. EV/EBITDA tells the same story: 6.0x in FY2024 versus a 20-year median of 18.4x.

7. Peer comparison — the value gap is real

Centene trades at the lowest P/S in the entire managed-care universe — about half of pure-play Molina and roughly a sixth of UnitedHealth. The fundamental gap is real: CNC's 2025 net margin of -3.4% sits well below every peer because the goodwill impairment is concentrated here, and the operating-margin gap to UNH (8.0%) reflects Optum's structural insulation that Centene has no equivalent for. But the magnitude — UNH at 0.72x P/S vs CNC at 0.11x — implies a permanent 80% earnings discount that only makes sense if you believe Medicaid + Marketplace + PDP are structurally broken business lines, not cyclically pressured ones.

8. Fair value — three scenarios

The 2026 adjusted-EPS guide of "greater than $3.00" is the only forward number that matters. Three scenarios pivot on whether the 91.9% Health Benefits Ratio in 2025 mean-reverts.

The skew is asymmetric: roughly 8% upside to the base case, 79% upside to the bull case, and 34% downside to the bear case. That positive expected value is the entire bullish thesis — if you believe HBR mean-reversion is the base case rather than the bull case. The market currently disagrees: at $41.82, the stock is pricing roughly $3.00 of run-rate EPS at a 14x multiple, which is the base case minus the recovery.

What the numbers say

The numbers confirm the bull story on three dimensions: balance sheet flexibility (net debt near zero, investment-grade through the impairment), cash conversion (10-year CFO/NI of 4.8x, FCF unaffected by GAAP volatility), and valuation extremity (P/S at a 20-year low, EV/EBITDA at half its long-run median). They contradict the popular narrative that this is a structurally broken business — operating margins have lived in a 1–3% band for two decades, the FY2025 GAAP loss is overwhelmingly goodwill impairment, and revenue still compounded 19% in the worst year. What to watch are the 2026 quarterly Health Benefits Ratio prints — if Q1/Q2 2026 Medicaid HBR holds at or below 93% and Marketplace HBR runs sub-90%, the rate-catch-up is working and the bull case rebuilds; if either drifts higher, the bear case accelerates and the multiple compresses again. One quarter from now the picture will be much clearer than it is today.